Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Trial, Randomized, Multicentre, Double Blind to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis

NCT04282941 is registered in ClinicalTrials.gov with Instituto de Investigación Hospital Universitario La Paz as lead sponsor.

NCT NCT04282941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04282941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Trial, Randomized, Multicentre, Double Blind to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis
Lead sponsor
Instituto de Investigación Hospital Universitario La Paz
Phase
Phase 3
Overall status
Unknown status
Start date
February 20, 2017
Completion date
November 30, 2020
Enrollment
180 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

persistent ductus arteriosus